A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Sponsor
Eli Lilly and Company
Study ID
NCT03861052
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.

Key Dates

Start date
May 7, 2019
Status verified
Apr 2022
Primary completion
Mar 10, 2021
Completion
Mar 31, 2021

Study Design

Enrollment
636 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 5 mg Tirzepatide
    Participants received 5 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 52 weeks.
  • Experimental: 10 mg Tirzepatide
    Participants received 10 mg tirzepatide administered SC once weekly for 52 weeks.
  • Experimental: 15 mg Tirzepatide
    Participants received 15 mg tirzepatide administered SC once weekly for 52 weeks.
  • Active Comparator: 0.75 mg Dulaglutide
    Participants received 0.75 mg dulaglutide administered SC once weekly for 52 weeks.

Primary Outcome Measure

Change From Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 52 ]

Related Studies